Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246878 · ClinicalTrials.gov registry record · Phase 1
A Study of EDP-235 in Healthy Subjects
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05246878 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT05246878, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG EDP-235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-01-28 |
| Est. Completion | 2022-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05246878
The ClinicalTrials.gov registry entry for NCT05246878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05246878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05246878 about?
NCT05246878 is a clinical study titled "A Study of EDP-235 in Healthy Subjects". This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
What is the current status of trial NCT05246878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-01-28. Estimated completion is 2022-07-20.
What interventions are being tested in trial NCT05246878?
The interventions under investigation include: Placebo (DRUG), EDP-235 (DRUG).
Who is sponsoring clinical trial NCT05246878?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.